fda drug shortage list semaglutide The GLP-1 is over. What's next for the compounders? - Pharma Technology Focus tirzepatide removed from shortage list

Boehringer's BI 3034701: New Triple-Agonist in Phase 2 Boehringer's BI 3034701, a GLP-1/GIP/NPY2 triple agonist, entered Phase 2 for obesity

The doctors turnaround the prescription and follow-ups very quickly which is much appreciated

demonstrated, in addition to higher weight loss in the group treated with high-dose liraglutide 3.0 mg/day for 32 weeks, significant improvements not only of fasting glucose and HOMA-IR, but also of the post-load glucose measured by OGTT, OGTT-derived insulin sensitivity index (SIOGTT), and corrected the early insulin response to a glucose challenge (IGI/HOMA) compared to placebo [62]

Who Should and Shouldnt Consider This Combination

The study said patients prescribed weight-loss drugs by an endocrinologist or obesity specialist were likelier to stick with them longer